Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs

Group 1: Union Pacific - Union Pacific is recommended as a good stock to own by Jim Cramer, supported by BofA Securities analyst Ken Hoexter who maintained a Buy rating and raised the price target from $256 to $262 [1][1][1] - On the trading day, Union Pacific shares fell 0.4% to settle at $225.72 [5] Group 2: BioMarin Pharmaceutical - BioMarin agreed to acquire Inozyme for $4.00 per share in an all-cash transaction totaling approximately $270 million [1] - BioMarin shares fell 0.6% to settle at $57.16 [5] Group 3: ARS Pharmaceuticals - Jim Cramer expressed a positive outlook on ARS Pharmaceuticals, stating it has valuable technology that someone will pay for, especially after the company posted better-than-expected sales for the first quarter [2][2] - ARS Pharmaceuticals shares fell 2.4% to settle at $14.34 [5] Group 4: GitLab - GitLab's second-quarter sales guidance was below estimates, with adjusted EPS expected between 16 and 17 cents and revenue between $226 million and $227 million, compared to the analyst estimate of $227.16 million [2][2] - GitLab shares fell 10.6% to close at $43.37 [5] Group 5: NuScale Power - Jim Cramer indicated interest in buying NuScale Power if it conducts a stock offering, following a recent event with Oklo [3] - UBS analyst Jon Windham maintained a Neutral rating on NuScale Power and raised the price target from $17 to $34 [3] - NuScale Power shares jumped 20.4% to close at $41.60 [5]